PubMed · AIDS· Jesús Troya·· 10 天前
医学研究：Comorbidity burden and outcomes with long-acting cabotegravir plus rilpivirine in the RELATIVITY cohort.
Comorbidity burden and outcomes with long-acting cabotegravir plus rilpivirine in the RELATIVITY cohort.
AI 导读
原文摘录：In RELATIVITY, among 3118 virologically suppressed people with HIV switching to long-acting cabotegravir plus rilpivirine, 40.0% had at least one comorbidity and 16.8% had multimorbidity. … 2%) were similar across strata, suggesting that comorbidity burden alone should not preclude individualized use in routine care
来源：PubMed · AIDS · pubmed.ncbi.nlm.nih.gov